Skip header and navigation

Refine By

7739 records – page 1 of 774.

2B or not to be--the 45-year saga of the Montreal Platelet Syndrome.

https://arctichealth.org/en/permalink/ahliterature140851
Source
Thromb Haemost. 2010 Nov;104(5):903-10
Publication Type
Article
Date
Nov-2010
Author
Man-Chiu Poon
Margaret L Rand
Shannon C Jackson
Author Affiliation
Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada. mcpoon@ucalgary.ca
Source
Thromb Haemost. 2010 Nov;104(5):903-10
Date
Nov-2010
Language
English
Publication Type
Article
Keywords
Blood Coagulation - genetics
Blood Coagulation Tests - history
Blood Platelet Disorders - blood - genetics - history
Blood Platelets - metabolism - pathology
Canada
Genetic Predisposition to Disease
History, 20th Century
Humans
Mutation
Pedigree
Phenotype
Platelet Function Tests - history
Syndrome
von Willebrand Disease, Type 2 - blood - genetics - history
von Willebrand Factor - genetics - history
Abstract
Over 45 years ago, Montreal Platelet Syndrome was first described as a rare inherited platelet disorder characterised by macrothrombocytopenia with spontaneous platelet clumping, abnormal platelet shape change upon stimulation and a defect in platelet calpain. This syndrome has now been reclassified as type 2B von Willebrand disease with the V1316M VWF mutation in the only kindred ever reported. We herein revisit the historical platelet characteristics originally described in Montreal Platelet Syndrome in light of the new diagnosis. This paper will review the 45-year saga of Montreal Platelet Syndrome, a story that highlights the value of revisiting a rare diagnosis to look for a more common explanation.
PubMed ID
20838735 View in PubMed
Less detail

2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg.

https://arctichealth.org/en/permalink/ahliterature84543
Source
Int J Public Health. 2007;52(3):166-72
Publication Type
Article
Date
2007
Author
Reintjes Ralf
Wiessing Lucas
Author Affiliation
Department of Public Health, Faculty Life Sciences, Hamburg University of Applied Sciences, Hamburg, Germany. Ralf.Reintjes@rzbd.haw-hamburg.de
Source
Int J Public Health. 2007;52(3):166-72
Date
2007
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - prevention & control - therapy
Cost-Benefit Analysis
Europe - epidemiology
HIV Infections - epidemiology - prevention & control - therapy
Hepatitis C - epidemiology
Humans
Norway - epidemiology
Population Surveillance
Prevalence
Risk factors
Risk-Taking
Substance Abuse, Intravenous - epidemiology
Turkey - epidemiology
Abstract
OBJECTIVES: HIV/AIDS surveillance methods are under revision as the diversity of HIV epidemics is becoming more apparent. The so called "2nd generation surveillance (SGS) systems" aim to enhance surveillance by broadening the range of indicators to prevalence, behaviors and correlates, for a better understanding and a more complete and timely awareness of evolving epidemics. METHODS: Concepts of HIV SGS are reviewed with a special focus on injecting drug users, a major at-risk and hard to reach group in Europe, a region with mainly low or concentrated epidemics. RESULTS: The scope of HIV/AIDS surveillance needs to be broadened following principles of SGS. Specifically for IDUs we propose including hepatitis C data as indicator for injecting risk in routine systems like those monitoring sexually transmitted infections and information on knowledge and attitudes as potential major determinants of risk behavior. CONCLUSIONS: The suggested approach should lead to more complete and timely information for public health interventions, however there is a clear need for comparative validation studies to assess the validity, reliability and cost-effectiveness of traditional and enhanced HIV/AIDS surveillance systems.
PubMed ID
17958283 View in PubMed
Less detail

[3 cases of viral carriage detected during screening for HIV antibodies].

https://arctichealth.org/en/permalink/ahliterature226768
Source
Zh Mikrobiol Epidemiol Immunobiol. 1991 Mar;(3):16-8
Publication Type
Article
Date
Mar-1991
Author
E M Shelukhina
E V Chekunova
G R Matsevich
I A Okunev
S S Marennikova
M R Zak
Source
Zh Mikrobiol Epidemiol Immunobiol. 1991 Mar;(3):16-8
Date
Mar-1991
Language
Russian
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - immunology - prevention & control
Blood Donors
Carrier State - epidemiology - immunology - prevention & control
Enzyme-Linked Immunosorbent Assay
HIV Antibodies - blood
HIV Seropositivity - epidemiology - immunology
HIV-1 - immunology
Humans
Immunoblotting
Lithuania - epidemiology
Mass Screening - methods
Moscow - epidemiology
Risk factors
Abstract
The results of screening more than 23,000 serum samples from persons belonging to risk groups, as well as those not belonging to such groups, in Moscow, Vilnius and Klaipeda are presented. Screening was carried out with the use of an assay system manufactured by the Scientific and Industrial Amalgamation "Antigen" (USSR). In this screening 3 HIV carriers were detected; of these, 2 were foreign students from two African countries.
PubMed ID
1872091 View in PubMed
Less detail

[3 cases of visceral leishmaniasis, one in a HIV-positive man]

https://arctichealth.org/en/permalink/ahliterature8254
Source
Ugeskr Laeger. 1991 May 27;153(22):1591-2
Publication Type
Article
Date
May-27-1991
Author
U. Balslev
F. Jonsbo
J. Junge
K D Bentsen
Author Affiliation
Hvidovre Hospital, København.
Source
Ugeskr Laeger. 1991 May 27;153(22):1591-2
Date
May-27-1991
Language
Danish
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - complications - diagnosis
Adult
English Abstract
HIV Seropositivity - complications - diagnosis
Humans
Infant
Leishmaniasis, Visceral - complications - diagnosis - drug therapy
Male
Opportunistic Infections - etiology
Abstract
Three cases of visceral leishmaniasis (kala-azar) are presented. One of these was in a 43-year-old patient with AIDS who was infected in Southern Spain. Another was in a man aged 25 years infected in West Africa. These cases are the first two adults to be reported in Denmark. The third case was an 18 month old previously healthy boy, infected in Southern Spain. The symptomtology, diagnosis and treatment of the disease are discussed and it is stressed that serological diagnostic tests have limited value in HIV positive patients.
PubMed ID
2058021 View in PubMed
Less detail

A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA.

https://arctichealth.org/en/permalink/ahliterature82145
Source
Neurology. 2006 May 23;66(10):1470-5
Publication Type
Article
Date
May-23-2006
Author
Majamaa-Voltti K A M
Winqvist S.
Remes A M
Tolonen U.
Pyhtinen J.
Uimonen S.
Kärppä M.
Sorri M.
Peuhkurinen K.
Majamaa K.
Author Affiliation
Department of Internal Medicine, University of Oulu, Oulu, Finland. kirsi.majamaa-voltti@oulu.fi
Source
Neurology. 2006 May 23;66(10):1470-5
Date
May-23-2006
Language
English
Publication Type
Article
Keywords
Adult
Alleles
Blood Glucose - analysis
Cognition Disorders - genetics
DNA, Mitochondrial - genetics
Diabetes Mellitus - blood - genetics
Disease Progression
Electrocardiography, Ambulatory
Electroencephalography
Female
Finland - epidemiology
Follow-Up Studies
Hearing Loss, Sensorineural - genetics
Humans
Hypertrophy, Left Ventricular - genetics - ultrasonography
Lactates - blood
MELAS Syndrome - genetics - mortality
Male
Middle Aged
Mitochondria, Muscle - metabolism
Mosaicism
Neuropsychological Tests
Point Mutation
Pyruvates - blood
Abstract
OBJECTIVE: To follow the clinical course of patients with the mitochondrial DNA mutation 3243A>G for 3 years. METHODS: Thirty-three adult patients with the 3243A>G mutation entered a 3-year follow-up study. They were clinically evaluated annually, audiometry was performed, and samples were drawn for the analysis of blood chemistry and mutation heteroplasmy in leukocytes. Holter recording was performed three times during the follow-up and echocardiography, neuropsychological assessment, and quantitative EEG and brain imaging conducted at entry and after 3 years. RESULTS: The incidence of new neurologic events was low during the 3-year follow-up. Sensorineural hearing impairment (SNHI) progressed, left ventricular wall thickness increased, mean alpha frequency in the occipital and parietal regions decreased, and the severity of disease index (modified Rankin score) progressed significantly. The rate of SNHI progression correlated with mutation heteroplasmy in muscle. The increase in left ventricular wall thickness was seen almost exclusively in diabetic patients. Seven patients died during the follow-up, and they were generally more severely affected than those who survived. CONCLUSIONS: Significant changes in the severity of disease, sensorineural hearing impairment, left ventricular hypertrophy, and quantitative EEG were seen in adult patients with 3243A>G during the 3-year follow-up.
Notes
Comment In: Neurology. 2007 Jan 9;68(2):163-417210904
PubMed ID
16717204 View in PubMed
Less detail

A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study.

https://arctichealth.org/en/permalink/ahliterature49604
Source
J Clin Psychiatry. 2005 May;66(5):559-63
Publication Type
Article
Date
May-2005
Author
Kaisa M Saari
Sari M Lindeman
Kaisa M Viilo
Matti K Isohanni
Marjo-Riitta Järvelin
Liisa H Laurén
Markku J Savolainen
Hannu J Koponen
Author Affiliation
Department of Psychiatry, University of Oulu, PO Box 5000, 90014 Oulu, Finland. kaisa.saari@oulu.fi
Source
J Clin Psychiatry. 2005 May;66(5):559-63
Date
May-2005
Language
English
Publication Type
Article
Keywords
Adult
Antipsychotic Agents - adverse effects - therapeutic use
Cohort Studies
Comorbidity
Diet Therapy
Exercise
Female
Finland - epidemiology
Humans
Logistic Models
Male
Metabolic Syndrome X - epidemiology - prevention & control - therapy
Prevalence
Psychiatric Status Rating Scales
Research Support, Non-U.S. Gov't
Risk factors
Schizophrenia - diagnosis - drug therapy - epidemiology
Weight Loss
Abstract
OBJECTIVE: Schizophrenia is associated with a shortened life expectancy and increased somatic comorbidity with, e.g., cardiovascular disorders. One major risk factor for these disorders is the metabolic syndrome, which has been reported to have a higher frequency in schizophrenic patients. Our objective was to study the prevalence of metabolic syndrome in a population-based birth cohort. METHOD: The study sample consisted of 5613 members of the Northern Finland 1966 Birth Cohort who participated in the field study from 1997 to 1998. Subjects were divided into 4 diagnostic categories (DSM-III-R): (1) schizophrenia (N = 31), (2) other functional psychoses (N = 22), (3) nonpsychotic disorders (N = 105), and (4) no psychiatric hospital treatment (N = 5455, comparison group). Subjects were assessed for the presence of metabolic syndrome according to the criteria of the National Cholesterol Education Program. RESULTS: The prevalence of metabolic syndrome was higher in subjects with schizophrenia compared with the comparison group (19% vs. 6%, p = .010). The prevalence of metabolic syndrome in subjects with other psychoses was 5%. After controlling for sex, the results of logistic regression analysis showed that the risk of metabolic syndrome in schizophrenia was 3.7 (95% CI = 1.5 to 9.0). CONCLUSIONS: The high prevalence of metabolic syndrome in schizophrenia even at such a relatively young age underscores the need to select antipsychotic medications with no or little capability to induce metabolic side effects. Also, developing comprehensive efforts directed at controlling weight and diet and improving physical activity are needed.
PubMed ID
15889940 View in PubMed
Less detail

[4-year experience of the Lund model for HIV/AIDS prevention. Needle-exchange program as a bridge to continued care of drug addicts]

https://arctichealth.org/en/permalink/ahliterature8257
Source
Lakartidningen. 1991 May 8;88(19):1797, 1799
Publication Type
Article
Date
May-8-1991

6-Hydroxycleroda-3,13-dien-15,16-olide protects neuronal cells from lipopolysaccharide-induced neurotoxicity through the inhibition of microglia-mediated inflammation.

https://arctichealth.org/en/permalink/ahliterature149311
Source
Planta Med. 2010 Feb;76(2):120-7
Publication Type
Article
Date
Feb-2010
Author
Yu-Tzu Shih
Ya-Yun Hsu
Fang-Rong Chang
Yang-Chang Wu
Yi-Ching Lo
Author Affiliation
Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan.
Source
Planta Med. 2010 Feb;76(2):120-7
Date
Feb-2010
Language
English
Publication Type
Article
Keywords
Animals
Anti-Inflammatory Agents - isolation & purification - pharmacology - therapeutic use
Cell Death - drug effects
Cell Line, Tumor
Diterpenes - isolation & purification - pharmacology - therapeutic use
Enzyme Inhibitors - pharmacology
Humans
Inflammation - prevention & control
Inflammation Mediators - metabolism
Lipopolysaccharides
Microglia - drug effects
Neurons - drug effects
Neurotoxicity Syndromes - prevention & control
Phytotherapy
Plant Extracts - chemistry - pharmacology - therapeutic use
Polyalthia - chemistry
Rats
Rats, Sprague-Dawley
Abstract
Polyalthia longifolia var. pendula is used as an antipyretic agent in indigenous systems of medicine. Microglia-mediated inflammation plays an important role in the pathway leading to neuronal cell death in a number of neurodegenerative diseases. The aim of this study was to investigate the effects of 6-hydroxycleroda-3,13-dien-15,16-olide (PL3) extracted from Polyalthia longifolia var. pendula on lipopolysaccharide(LPS)-induced inflammation in microglia-like HAPI cells and primary microglia cultures. In microglia-neuron co-cultures, LPS decreased the cell viability of neuroblastoma SH-SY5Y cells. LPS-induced cell death was attenuated by the NOS inhibitor, L-NAME, the COX-2 inhibitor, NS-398 or the NADPH oxidase inhibitor, DPI, respectively. In LPS-treated microglia cells, PL3 decreased the expression of iNOS, COX-2, gp91 (phox), and NF- kappaBp65, the degradation of I kappaB alpha, and the production of NO, PGE (2), iROS, and TNF- alpha. PL3 also enhanced the expression of HO-1, a cytoprotective and anti-inflammatory enzyme. Moreover, PL3 reduced LPS-activated microglia-induced cell death. The present results suggest that PL3 inhibits microglia-mediated inflammation and inflammation-related neuronal cell death. Therefore, PL3 has potential use for the treatment of inflammation-related neurodegenerative diseases.
PubMed ID
19653144 View in PubMed
Less detail

7739 records – page 1 of 774.